{"id":34522,"date":"2023-01-13T09:24:26","date_gmt":"2023-01-13T08:24:26","guid":{"rendered":"https:\/\/ellipse.prbb.org\/?p=34522"},"modified":"2023-01-13T09:24:30","modified_gmt":"2023-01-13T08:24:30","slug":"nova-via-per-superar-la-resistencia-al-tractament-en-un-tipus-de-leucemia","status":"publish","type":"post","link":"https:\/\/ellipse.prbb.org\/ca\/nova-via-per-superar-la-resistencia-al-tractament-en-un-tipus-de-leucemia\/","title":{"rendered":"Nova via per superar la resist\u00e8ncia al tractament en un tipus de leuc\u00e8mia"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">La <strong><a href=\"https:\/\/ellipse.prbb.org\/ca\/que-es-la-leucemia-i-per-que-apareix\/\" target=\"_blank\" rel=\"noreferrer noopener\">leuc\u00e8mia<\/a> limfobl\u00e0stica aguda de c\u00e8l\u00b7lules T <\/strong>\u00e9s una malaltia rara, que es diagnostica a un centenar de persones cada any a l&#8217;Estat, i afecta sobretot als infants. Alguns pacients no responen b\u00e9 a la quimioter\u00e0pia habitual. Gr\u00e0cies a <a href=\"https:\/\/www.imim.cat\/noticies\/1144\/identifiquen-una-via-per-superar-la-resistencia-al-tractament-en-un-tipus-de-leucemia\" target=\"_blank\" rel=\"noreferrer noopener\">un estudi <\/a>encap\u00e7alat per investigadores de l&#8217;<a rel=\"noreferrer noopener\" href=\"http:\/\/www.imim.es\/\" target=\"_blank\">Institut Hospital del Mar d\u2019Investigacions M\u00e8diques&nbsp;(IMIM)<\/a>, ara no tan sols es podr\u00e0 <strong>saber <\/strong>amb antel\u00b7laci\u00f3 quines persones<strong> tenen una major probabilitat de <a rel=\"noreferrer noopener\" href=\"https:\/\/ellipse.prbb.org\/ca\/trencar-la-barrera-que-les-cellules-de-cancer-colorectal-creen-contra-la-quimioterapia\/\" target=\"_blank\">no respondre a la quimioter\u00e0pia<\/a><\/strong>, sin\u00f3 que es podria eliminar la resist\u00e8ncia a aquest tractament.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">De fet el treball, realitzat pel<a rel=\"noreferrer noopener\" href=\"https:\/\/ellipse.prbb.org\/ca\/anna-bigas-grup-de-recerca-en-cel%c2%b7lules-mare-i-cancer\/\" target=\"_blank\"> Grup de Recerca en C\u00e8l\u00b7lules Mare<\/a> dirigit per l\u2019<a href=\"https:\/\/ellipse.prbb.org\/ca\/de-dones-liders-a-talent-africa-celebrant-la-diversitat-en-la-ciencia\/\" target=\"_blank\" rel=\"noreferrer noopener\">Anna Bigas<\/a>, ha demostrat, en un <strong><a href=\"https:\/\/ellipse.prbb.org\/ca\/els-animals-en-la-recerca-biomedica\/\" target=\"_blank\" rel=\"noreferrer noopener\">model de ratol\u00ed<\/a><\/strong>, que <strong>combinar la quimioter\u00e0pia amb un inhibidor de la prote\u00efna beta-catenina <\/strong>pot <strong>eliminar la resist\u00e8ncia <\/strong>al tractament. Els autors creuen que aquesta combinaci\u00f3 podr\u00eda tamb\u00e9 millorar la resposta en els casos en qu\u00e8 el tractament ja funciona.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Utilitzant tant mostres de pacients com models animals, l\u2019equip ha confirmat el <strong>paper de la beta-catenina en la formaci\u00f3 de la leuc\u00e8mia<\/strong>, a trav\u00e9s de la seva acci\u00f3 sobre <strong>79 gens<\/strong>. \u00abAra estem mirant quins d&#8217;aquests gens s\u00f3n m\u00e9s informatius i podrien orientar el diagn\u00f2stic de la resposta dels pacients a la quimioter\u00e0pia convencional\u00bb, diu Bigas, que \u00e9s tamb\u00e9 vicedirectora de Recerca Precl\u00ednica de l&#8217;Institut de Recerca Contra la Leuc\u00e8mia Josep Carreras.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les properes pases seran fer estudis amb c\u00e8l\u00b7lules de pacients humans en ratolin i, en cas positiu, posar en marxa un<a href=\"https:\/\/ellipse.prbb.org\/ca\/iris-lioba-matilla-vaz-imim-sense-assaigs-clinics-la-medicina-no-podria-avancar\/\" target=\"_blank\" rel=\"noreferrer noopener\"> assaig cl\u00ednic en humans<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un estudi de l\u2019IMIM ha revelat el paper clau de la beta-catenina per indicar els pacients amb leuc\u00e8mia limfobl\u00e0stica aguda de c\u00e8l\u00b7lules T que no respondran al tractament habitual i superar aquesta resist\u00e8ncia.<\/p>\n","protected":false},"author":6,"featured_media":34526,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[213,635,205],"new-type":[35],"class_list":["post-34522","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recerca","tag-imim","tag-leucemia","tag-organismes-model","new-type-noticies"],"acf":[],"_links":{"self":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/34522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/comments?post=34522"}],"version-history":[{"count":4,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/34522\/revisions"}],"predecessor-version":[{"id":34552,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/34522\/revisions\/34552"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media\/34526"}],"wp:attachment":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media?parent=34522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/categories?post=34522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/tags?post=34522"},{"taxonomy":"new-type","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/new-type?post=34522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}